Option Care Health, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. Option Care Health provides infusion therapy and related services through 93 full-service pharmacies and 84 ambulatory infusion suites, operating as one infusion-services segment.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $1,146.1 million | $1,015.8 million; up 12.8% |
| Gross profit / margin | $238.5 million / 20.8% | $229.0 million / 22.5% |
| Operating income / margin | $69.0 million / 6.0% | $66.6 million / 6.6% |
| Net income / diluted EPS | $44.8 million / $0.26 | $39.2 million / $0.21 diluted EPS |
| Operating cash flow | $(68.8) million | $89.8 million provided |
| Cash and equivalents | $219.5 million at March 31 | $343.8 million at December 31, 2023 |
| Debt | $1,086.5 million principal; $1,062.3 million carrying value | $400 million revolver; $394.7 million available net of letters of credit |
Cost of revenue was $907.6 million, or 79.2% of revenue, versus 77.5% a year earlier. SG&A was $154.7 million, up 4.7%, but declined to 13.5% of revenue from 14.6%. Net interest expense was $13.2 million. The company reported $5.8 million of capital expenditures and repaid $1.5 million of debt principal.
Material changes and drivers
- Revenue growth was attributed to organic growth across therapies: chronic revenue grew in the mid-teens, while acute revenue had single-digit growth. Commercial payers contributed $988.0 million of revenue; government payers, $138.3 million.
- Gross margin fell 1.7 percentage points. Management cited the absence of temporary favorable therapy-pricing dynamics from the prior-year quarter, therapy mix, and acute drug supply-chain disruption.
- Net income rose 14.2%, reflecting organic growth and lower tax expense. The effective tax rate declined to 21.4% from 27.7%; Q1 2024 included a $2.2 million release of state valuation allowance.
- Accounts receivable increased to $573.7 million from $377.7 million at year-end. Management attributed the operating cash-flow deterioration primarily to delayed claims processing and collections associated with the Change Healthcare cybersecurity incident.
- The company repurchased 1.25 million shares for $40.0 million at an average $31.96 per share, leaving approximately $210.0 million authorized under its repurchase program.
Outlook, risks, and unusual items
- Change Healthcare’s February 2024 cybersecurity incident disrupted claims processing. Option Care Health said it had not identified compromise of its own systems, had resumed claims submissions to several payers and used alternatives for most claims, and was working through accumulated unprocessed claims. It expected affected operating cash flows to be recognized later in 2024; it reported no material impact to Q1 financial results and did not consider a material overall impact reasonably likely.
- Management believes existing cash, expected operating cash flows, and planned capital spending will be sufficient for operating requirements over the next 12 months and beyond. Future acquisitions could require additional capital, and financing availability on acceptable terms is not assured.
- Risks include reimbursement and collection delays, payer and government-program reimbursement uncertainty, reliance on a small number of suppliers (four vendors represented about 66% of pharmaceutical and medical-supply purchases), and exposure to variable interest rates. The largest payer accounted for approximately 14% of revenue.
- Debt principal was $1.087 billion, including a $586.5 million term loan with an 8.19% period-end rate and $500 million of senior notes bearing 4.375%. The term loan and notes mature in 2028 and 2029, respectively. The company uses a $300 million interest-rate cap to partially hedge variable-rate exposure.
- The company is involved in legal proceedings, investigations, audits, and inquiries in the ordinary course. It said pending matters, after reserves and indemnification, were not expected to materially affect the balance sheet, while acknowledging that unexpected outcomes could affect results or cash flows.
Important facts for investors to verify
- Whether delayed claims from the Change Healthcare incident are processed and collected as expected, and how receivables and operating cash flow recover during 2024.
- Whether revenue growth can be sustained without further gross-margin pressure from therapy mix, pricing, or supply disruptions.
- Debt-service and liquidity trends, including the variable-rate term loan, cash levels, and use of the revolver or remaining share-repurchase authorization.
- Any developments in reimbursement estimates, supplier availability, government-program exposure, or legal and regulatory matters.